Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis

Table 4 Mean medical and pharmacy cost PPPM of PsA patients receiving anti-TNFα therapy for the 3-year follow-up^ab

	Patients With Only First-line Anti-TNFα Biologic Therapy (n = 881)^c	Patients With Second-line Anti-TNFα Biologic Therapy (n = 72)^c	Patients With Third-line or Greater Anti-TNFα Biologic Therapy (n = 37)^c
Medical Cost PPPM, Mean (SD)^d
First-line	$322 ($1854)	$127 ($247)	$282 ($595)
Second-line	N/A	$156 ($291)	$79 ($99)
Third-line or greater	N/A	N/A	$107 ($88.0)
Overall	$322 ($1854)	$167 ($363)	$217 ($86.0)
Pharmacy Cost PPPM Mean (SD)^e
First-line	$1985 ($833)	$2082 ($836)	$2515 ($1800)
Second-line	N/A	$2114 ($778)	$2947 ($1927)
Third-line or greater	N/A	N/A	$2126 ($2551)
Overall	$1985 ($833)	$2045 ($650)	$2539 ($1115)

^aThe value for each of the medical and pharmacy costs was calculated as total PPPM cost incurred from initiation of an anti-TNFα biologic treatment to discontinuation of treatment or end of the 3-year follow-up period (whichever came first) divided by the number of covered members per months from initiation to treatment discontinuation or end of the follow-up period (whichever came first)
^bCosts of capitation patients were replaced with fee-for-service proxy; all costs were adjusted by consumer price index
^cBiologic therapy refers to the following anti-TNFα agents: etanercept, adalimumab, infliximab, and golimumab
^dMedical cost = hospitalization cost + ER cost + office visit cost. Number of months is defined as the rounding of number of days on treatment divided by 30. If number of months equals to 0, then it is assigned as 1
^ePharmacy cost = Biologic treatment cost + DMARD treatment cost
DMARD disease-modifying antirheumatic drug, ER emergency room, PsA psoriatic arthritis, PPPM per patient per month, SD standard deviation, TNFα tumor necrosis factor-α

ISSN: 1471-2474